Cost of ventricular assist devices can we afford the progress?

Circulation

Volumn 127, Issue 6, 2013, Pages 743-748

  Miller, Leslie W ^a   Guglin, Maya ^a   Rogers, Joseph ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARVEDILOL; CLENBUTEROL; ENALAPRIL MALEATE; HYDRALAZINE PLUS ISOSORBIDE DINITRATE;

ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; COST EFFECTIVENESS ANALYSIS; FUNCTIONAL STATUS; HEALTH CARE COST; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; LONGEVITY; MEDICARE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL TIME; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; HEART FAILURE; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS;

EID: 84873916543     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.139824     Document Type: Article

References (39)

1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Stafford R, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation. 2010;121:948-954.
2. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
3. Bogner HR, Miller SD, de Vries HF, Chhatre S, Jayadevappa R. Assessment of cost and health resource utilization for elderly patients with heart failure and diabetes mellitus. J Card Fail. 2010;16:454-460.
4. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. Pharmacoeconomics. 2008;26:447-462.
5. Lee WC, Chavez YE, Baker T, Luce BR. Economic burden of heart failure: a summary of recent literature. Heart Lung. 2004;33:362-371.
6. Gelijns AC, Richards AF, Williams DL, Oz MC, Oliveira J, Moskowitz AJ. Evolving costs of long-term left ventricular assist device implantation. Ann Thorac Surg. 1997;64:1312-1319.
7. Russo MJ, Gelijns AC, Stevenson LW, Sampat B, Aaronson KD, Renlund DG, Ascheim DD, Hong KN, Oz MC, Moskowitz AJ, Rose EA, Miller LW; REMATCH Investigators. The cost of medical management in advanced heart failure during the final two years of life. J Card Fail. 2008;14:651-658.
8. Rogers JG, Butler J, Lansman SL, Gass A, Portner PM, Pasque MK, Pierson RN III; INTrEPID Investigators. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. J Am Coll Cardiol. 2007;50:741-747.
9. Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, Long JW, Ascheim DD, Tierney AR, Levitan RG, Watson JT, Meier P, Ronan NS, Shapiro PA, Lazar RM, Miller LW, Gupta L, Frazier OH, Desvigne-Nickens P, Oz MC, Poirier VL; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345:1435-1443.
10. Park SJ, Milano CA, Tatooles AJ, Rogers JG, Adamson RM, Steidley DE, Ewald GA, Sundareswaran KS, Farrar DJ, Slaughter MS; HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail. 2012;5:241-248.
11. Miller LW. Left ventricular assist devices are underutilized. Circulation. 2011;123:1552-8; discussion 1558.
12. Goldman L, Gordon DJ, Rifkind BM, Hulley SB, Detsky AS, Goodman DW, Kinosian B, Weinstein MC. Cost and health implications of cholesterol lowering. Circulation. 1992;85:1960-1968.
13. Rich MW, Nease RF. Cost-effectiveness analysis in clinical practice: the case of heart failure. Arch Intern Med. 1999;159:1690-1700.
14. Bryant J, Brodin H, Loveman E, Payne E, Clegg A. The clinical and costeffectiveness of implantable cardioverter defibrillators: a systematic review. Health Technol Assess. 2005;9:1-150, iii.
15. Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model. Health Technol Assess. 2007;11:iii-iv, ix.
16. Digiorgi PL, Reel MS, Thornton B, Burton E, Naka Y, Oz MC. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant. 2005;24:200-204.
17. Kottke TE, Pesch DG, Frye RL, McGoon DC, Warnes CA, Kurland LT. The potential contribution of cardiac replacement to the control of cardiovascular diseases. A population-based estimate. Arch Surg. 1990;125:1148-1151.
18. John R, Boyle A, Pagani F, Miller L. Physiologic and pathologic changes in patients with continuous-flow ventricular assist devices. J Cardiovasc Transl Res. 2009;2:154-158.
19. Russell SD, Rogers JG, Milano CA, Dyke DB, Pagani FD, Aranda JM, Klodell CT Jr, Boyle AJ, John R, Chen L, Massey HT, Farrar DJ, Conte JV; HeartMate II Clinical Investigators. Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation. 2009;120:2352-2357.
20. Miller LW. Is pulsatile blood flow no longer essential? Circulation. 2009;120:2313-2314.
21. Left-ventricular assist devices as destination therapy for end-stage heart failure. TEC bulletin (Online). 2002;19:28-30.
22. Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006;355:1873-1884.
23. Kirklin JK, Naftel DC, Kormos RL, Stevenson LW, Pagani FD, Miller MA, Baldwin JT, Young JB. The Fourth INTERMACS Annual Report: 4, 000 implants and counting. J Heart Lung Transplant. 2012;31: 117-126.
24. Boyle AJ, Ascheim DD, Russo MJ, Kormos RL, John R, Naka Y, Gelijns AC, Hong KN, Teuteberg JJ. Clinical outcomes for continuous-flow left ventricular assist device patients stratified by pre-operative INTERMACS classification. J Heart Lung Transplant. 2011;30:402-407.
25. Eckman P, Rosenbaum, A, Duval, S, Kamdar, P, Milavitz, B, John, R. Cost and length of stay for implant of continuous flow left ventricular assist device (cf-lvad) in patients with intermacs profiles 4-6 are lower than patients with intermacs profiles 1-3. The J Heart Lung Transplant.. 2012;30:S44-S45.
26. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
27. Us renal data system, usrds 2001 annual report: Atlas of chronic kidney disease and end-stage renal disease in the united states. National Institutes of Health, National Institute of Diabetes, Gastrointestinal and Kidney Diseases, Bethesda Maryland, 2011.
28. Williams ML, Trivedi JR, McCants KC, Prabhu SD, Birks EJ, Oliver L, Slaughter MS. Heart transplant vs left ventricular assist device in heart transplant-eligible patients. Ann Thorac Surg. 2011;91:1330-3; discussion 1333.
29. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado RM III, Long JW, Wozniak TC, Ghumman W, Farrar DJ, Frazier OH; HeartMate II Investigators. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009;361:2241-2251.
30. Bostic RR. Heart transplant and left ventricular assist device costs. J Heart Lung Transplant. 2005;24:1997-1998.
31. Moskowitz AJ, Rose EA, Gelijns AC. The cost of long-term LVAD implantation. Ann Thorac Surg. 2001;71(3 Suppl):S195-8; discussion S203.
32. Adamson R, Jaski B, Hoagland P, Baradarian S, Chammas, J, Norman, V, Chillcott, C, Stahovich, M, Ortiz, K, McCalmont, V, Hazard, L, Dembitsky, WP. Cost comparison of heartmate ii implantation and cardiac transplantation. The J Heart Lung Transplant.. 2012;30:S61.
33. Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012;5:10-16.
34. Clegg AJ, Scott DA, Loveman E, Colquitt J, Royle P, Bryant J. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for people with end-stage heart failure: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2007;23:261-268.
35. Miller LW, Nelson KE, Bostic RR, Tong K, Slaughter MS, Long JW. Hospital costs for left ventricular assist devices for destination therapy: lower costs for implantation in the post-REMATCH era. J Heart Lung Transplant. 2006;25:778-784.
36. Moreno SG, Novielli N, Cooper NJ. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation. J Heart Lung Transplant. 2012;31:450-458.
37. Slaughter MS, Bostic R, Tong K, Russo M, Rogers JG. Temporal changes in hospital costs for left ventricular assist device implantation. J Card Surg. 2011;26:535-541.
38. Rogers JG, Bostic RR, Tong KB, Adamson R, Russo M, Slaughter MS. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012;5:10-16.
39. Goldstein D, Sileo, A, Baker, L, Vandevoort, K, Cotter P. Contemporary continuous flow devices: How much does it cost to keep a patient on support for one year? The J Heart Lung Transplant.. 2012;30:S85.